SB-AD-002

ScandiBio Therapeutics is a clinical-stage biotechnology company based in Stockholm, Sweden, that leverages AI and systems biology to develop therapies for metabolic and neurodegenerative diseases. Founded in 2017 by a team of prominent researchers from KTH Royal Institute of Technology and Karolinska Institutet, the company focuses on restoring mitochondrial function through rationally designed combinations of metabolic cofactors. Its lead program, SB-AD-002 (also known as CMA2), is a Phase 3 candidate for Alzheimer's disease consisting of N-acetyl-L-cysteine, L-carnitine-L-tartrate, nicotinamide, and L-serine. This "Combined Metabolic Activator" (CMA) approach aims to simultaneously enhance NAD+ levels, promote fatty acid oxidation, and reduce oxidative stress. ScandiBio's platform integrates multi-omics data to identify therapeutic targets and has generated a pipeline that includes treatments for Parkinson's disease and metabolic disorders.